HUTCHMED Announces NDA Acceptance In China With Priority Review Status For ORPATHYS® And TAGRISSO® Combination In Lung Cancer Patients With MET Amplification After Progression On First-Line EGFR Inhibitor Therapy

(MENAFN - GlobeNewsWire - Nasdaq) HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 02, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (–HUTCHMED–) (Nasdaq/AIM:HCM; HKEX:13) today announces ...Ads Links by Easy Branches
Play online games for free at games.easybranches.com

Guest Post Services www.easybranches.com/contribute